Towards potent anti-inflammatory therapies in atherosclerosis: The case of methotrexate and colchicine combination into compartmentalized liposomes

[1]  Chao Li,et al.  Colchicine-Containing Nanoparticles Attenuates Acute Myocardial Infarction Injury by Inhibiting Inflammation , 2021, Cardiovascular Drugs and Therapy.

[2]  P. Decuzzi,et al.  Synthesis of Two Methotrexate Prodrugs for Optimizing Drug Loading into Liposomes , 2021, Pharmaceutics.

[3]  P. Decuzzi,et al.  Modulating Lipoprotein Transcellular Transport and Atherosclerotic Plaque Formation in ApoE–/– Mice via Nanoformulated Lipid–Methotrexate Conjugates , 2020, ACS applied materials & interfaces.

[4]  Bo Yu,et al.  Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway , 2020, Oxidative medicine and cellular longevity.

[5]  D. S. Mehta,et al.  Quantitative assessment of morphology and sub-cellular changes in macrophages and trophoblasts during inflammation. , 2020, Biomedical optics express.

[6]  P. Decuzzi,et al.  Optimizing the Pharmacological Properties of Discoidal Polymeric Nanoconstructs Against Triple-Negative Breast Cancer Cells , 2020, Frontiers in Bioengineering and Biotechnology.

[7]  Jiayue Shi,et al.  An injectable thermosensitive hydrogel loaded with an ancient natural drug colchicine for myocardial repair after infarction. , 2020, Journal of materials chemistry. B.

[8]  K. Parang,et al.  Design and Biological Evaluation of Colchicine-CD44-Targeted Peptide Conjugate in an In Vitro Model of Crystal Induced Inflammation , 2019, Molecules.

[9]  P. Psaltis,et al.  Inflammation as a Therapeutic Target in Atherosclerosis , 2019, Journal of clinical medicine.

[10]  Christian Celia,et al.  Mathematical Modeling of Release Kinetics from Supramolecular Drug Delivery Systems , 2019, Pharmaceutics.

[11]  V. Kraus,et al.  Colchicine--Update on mechanisms of action and therapeutic uses. , 2015, Seminars in arthritis and rheumatism.

[12]  D. Cines,et al.  α-Defensins Induce a Post-translational Modification of Low Density Lipoprotein (LDL) That Promotes Atherosclerosis at Normal Levels of Plasma Cholesterol* , 2015, The Journal of Biological Chemistry.

[13]  M. Bittencourt,et al.  Statin effects on atherosclerotic plaques: regression or healing? , 2015, BMC Medicine.

[14]  H. Mayan,et al.  Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. , 2014, Autoimmunity reviews.

[15]  Tingting Wang,et al.  Modulation of macrophage phenotype by cell shape , 2013, Proceedings of the National Academy of Sciences.

[16]  Divya Agarwal,et al.  Low‐dose and high‐dose methotrexate are two different drugs in practical terms , 2010, International journal of rheumatic diseases.

[17]  G. Sangiorgi,et al.  Role of Inflammation in Atherosclerosis* , 2007, Journal of Nuclear Medicine.

[18]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[19]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[20]  A. C. Nicholson,et al.  CD36, oxidized LDL and PPARγ: pathological interactions in macrophages and atherosclerosis , 2004 .

[21]  S. Mao,et al.  Stimulation of smooth muscle cell proliferation by ox-LDL- and acetyl LDL-induced macrophage-derived foam cells. , 2001, Life sciences.

[22]  R. Straub,et al.  Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[23]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[24]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[25]  J. Folkman,et al.  Role of cell shape in growth control , 1978, Nature.